Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Hims & Hers Health, Inc.HIMS · Entity 1878 | Director | August 14, 2026 | August 18, 2026 |
| INTERNATIONAL FLAVORS & FRAGRANCES INCIFF · Entity 3234 | Director | May 04, 2022 | May 06, 2022 |
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | Director · President and CEO | November 01, 2022 | November 02, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Hims & Hers Health, Inc.
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 26,020 |
Reported balance
After 2026-08-14 transaction · row 1
1 source rowRow 1 · 2026-08-14 · Exercise / conversion · Acquired 6,623 · Balance 26,020 F1: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 6,624 |
Reported balance
After 2026-08-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-14 · Exercise / conversion · Disposed 6,623 · Balance 6,624 F1: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU. F2: Subject to continuous service, the RSUs under the award will vest in three substantially equal installments, with one-third of the RSUs vesting on the first Company quarterly vesting date to occur after each of the first, second, and third anniversaries of the director's service commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted Restricted Stock Units ("RSUs") which represent a contingent right to receive one share of Class A Common Stock for each RSU.
F2: Subject to continuous service, the RSUs under the award will vest in three substantially equal installments, with one-third of the RSUs vesting on the first Company quarterly vesting date to occur after each of the first, second, and third anniversaries of the director's service commencement date.
INTERNATIONAL FLAVORS & FRAGRANCES INC
Report date May 04, 2022 · Filed May 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,344 |
Reported balance
After 2022-05-05 transaction · row 1
1 source rowRow 1 · 2022-05-05 · Exercise / conversion · Acquired 1,089 · Balance 1,344 F1: Upon the vesting of Restricted Stock Units ("RSUs") on May 5, 2022, the reporting person did not defer the receipt of 1,089 shares of Common Stock pursuant to IFF's deferred compensation plan. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2023-05-04 | Direct | 1,245 |
Reported balance
After 2022-05-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-04 · Grant · Acquired 1,245 · Balance 1,245 F2: The RSUs convert to Common Stock on a one-for-one basis. F3: Represent RSUs granted under the Non-Employee Director Compensation Program. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Expires 2022-05-05 | Direct | 0 |
Reported balance
After 2022-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-05 · Exercise / conversion · Disposed 1,089 · Balance 0 F2: The RSUs convert to Common Stock on a one-for-one basis. F1: Upon the vesting of Restricted Stock Units ("RSUs") on May 5, 2022, the reporting person did not defer the receipt of 1,089 shares of Common Stock pursuant to IFF's deferred compensation plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Upon the vesting of Restricted Stock Units ("RSUs") on May 5, 2022, the reporting person did not defer the receipt of 1,089 shares of Common Stock pursuant to IFF's deferred compensation plan.
F2: The RSUs convert to Common Stock on a one-for-one basis.
F3: Represent RSUs granted under the Non-Employee Director Compensation Program.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date November 01, 2022 · Filed November 02, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 1,542,471 |
Reported balance
After 2022-11-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-11-01 · Exercise / conversion · Acquired 116,389 · Balance 1,542,471 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-11-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-01 · Exercise / conversion · Disposed 116,389 · Balance 0 F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3: Restricted share units were granted on November 3, 2017 with 63,613 vested on November 3, 2019, 180,000 vested on each of November 1, 2020 and November 1, 2021 and 116,389 vested on November 1, 2022. F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F3: Restricted share units were granted on November 3, 2017 with 63,613 vested on November 3, 2019, 180,000 vested on each of November 1, 2020 and November 1, 2021 and 116,389 vested on November 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2020 Filed Feb 11, 2020 12:04 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 26,867 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-008168 · doc4.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| November 03, 2019 Filed Nov 5, 2019 12:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 63,613 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-055063 · doc4.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 476,389 Underlying: Ordinary Shares · 63,613 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on November 3, 2017, with 63,613 vesting on November 3, 2019, 180,000 vesting on each of November 1, 2020 and November 1, 2021 and 116,389 vesting on November 1, 2022. F3 · derivative.expiration_date: Restricted share units were granted on November 3, 2017, with 63,613 vesting on November 3, 2019, 180,000 vesting on each of November 1, 2020 and November 1, 2021 and 116,389 vesting on November 1, 2022. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| November 03, 2019 Filed Nov 5, 2019 12:19 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 63,613 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-055063 · doc4.xml · nonDerivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 12:28 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 179,104 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017236 · doc4.xml · derivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,104 Underlying: Ordinary Shares · 179,104 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F2 · derivative.exercise_date: Restricted share units were granted on March 4, 2019, with 59,701 vesting on each of March 4, 2021 and March 4, 2022 and 59,702 vesting on March 4, 2023. F2 · derivative.expiration_date: Restricted share units were granted on March 4, 2019, with 59,701 vesting on each of March 4, 2021 and March 4, 2022 and 59,702 vesting on March 4, 2023. F3 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 80,601 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009205 · doc4.xml · derivative · entry 2 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,601 Underlying: Ordinary Shares · 80,601 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 26,867 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F4 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 26,867 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:25 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantStock Options (right to buy) · Derivative | 205,482 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001209191-18-009205 · doc4.xml · derivative · entry 1 Schultz Kare · CIK 0001724567 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,482 Underlying: Ordinary Shares · 205,482 shares Expires 2028-02-08 F1 · derivative.exercise_date: Stock options were granted on February 9, 2018, with 68,494 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.